3 completed, 1 enrolling by invitation, 1 recruiting, 1 terminated. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 3, Enrolling by invitation 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow CT-P13: new trials by email Literature Review of CT-P13 trials Research Report on CT-P13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease TDM-based infliximab intravenous therapy, Standard infliximab intravenous therapy - Crohn Disease, Infliximab | Phase 4 | Recruiting | Asan Medical Center | 86 | 2023-11-01 | 2024-05-14 |
| Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis Remsima - Psoriasis | Phase 4 | Completed | Ghurki Trust and Teaching Hospital | 51 | 2022-03-10 | 2023-09-21 |
| REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) Adalimumab and its biosimilars, Biological: Etanercept and its biosimilars, Golimumab - Ankylosing Spondylitis, Axial Spondyloarthritis | Phase 4 | Unknown | Hanyang University Seoul Hospital | 448 | 2022-01-15 | 2021-12-20 |
| Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL) Infliximab CT-P13, Immunosuppressors (Thiopurines or Methotrexate) - Crohn Disease | Phase 4 | Completed | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 213 | 2021-12-21 | 2026-11-06 |
| De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease Infliximab, Adalimumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Enrolling by invitation | University Medical Center Groningen | 148 | 2021-03-11 | 2025-01-06 |
| TITRATE (inducTIon for acuTe ulceRATivE Colitis) Infliximab - Colitis, Ulcerative | Phase 4 | Terminated | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-09-04 | 2025-02-06 |
| The NOR-SWITCH Study Innovator infliximab, Biosimilar infliximab - Rheumatoid Arthritis, Spondyloarthritis | Phase 4 | Completed | Diakonhjemmet Hospital | 482 | 2014-10-01 | 2017-09-25 |
Crohn Disease (4) · Colitis, Ulcerative (3) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Axial Spondyloarthritis (1) · Inflammatory Bowel Diseases (1) · Psoriasis (1) · Spondylarthritis (1) · Spondylitis, Ankylosing (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asan Medical Center (1) · Diakonhjemmet Hospital (1) · Ghurki Trust and Teaching Hospital (1) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (1) · Hanyang University Seoul Hospital (1) · University Medical Center Groningen (1)
Netherlands (2) · Norway (2) · Belgium (1) · France (1) · Ireland (1) · Pakistan (1) · South Korea (1) · Spain (1)
Byong Duk Ye, MD, PhD (1) · Dr. Faria Asad (1) · Dr. Nabigha Khalid (1) · Dr. Saleha Batool (1) · Dr. Sumera Hanif (1) · Dr. Talat Masood Akbar (1) · Geert DHaens (1) · Patrick F van Rheenen, MD PhD (1) · Prof. Dr. Haroon Nabi (1) · Tae-Hwan Kim, MD, PhD (1) · Tore K. Kvien, MD PhD (1)
PMID 28502609, PMID 30762274, PMID 32965617, PMID 34732500, PMID 39390697
2014 (1)